Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders

Expert Opinion on Drug Metabolism & Toxicology
Alfredo Carlo AltamuraMassimiliano Buoli

Abstract

Fluvoxamine is one of the most widely prescribed antidepressants and presents data from 30 years of clinical experience. The present review article describes the pharmacokinetic properties of fluvoxamine and their implications for the treatment of anxiety disorders (AD). A search in the main database sources (Medline, Isi Web of Knowledge and Medscape) has been performed in order to obtain a comprehensive and balanced evaluation of fluvoxamine about the implications of its pharmacokinetic properties for the treatment of AD. The word 'fluvoxamine' has been associated with 'pharmacokinetics', 'interactions', 'generalized anxiety disorder', 'social anxiety disorder', 'social phobia', 'panic disorder', 'anxiety' and 'tolerability'. No restriction criteria were established in relation to methodology or year of publication. Only English-language articles have been selected. Fluvoxamine presents high tolerability and safety so that it can be considered as a therapeutic option in case of panic disorder and social anxiety disorder. In contrast, its weakness is in extended interaction with CYP450 enzymatic system that may limit its use in elderly or patients with medical comorbidities. Finally, data of efficacy about generalized anxiety ...Continue Reading

References

Oct 1, 1992·Clinical Pharmacology and Therapeutics·J van HartenA Cournot
Dec 1, 1991·International Clinical Psychopharmacology·J A Henry
Feb 1, 1990·Clinical Neuropharmacology·H A Kessler, A A Harris
Dec 1, 1987·The American Journal of Psychiatry·T L PerseR Dar
Jul 1, 1983·European Journal of Drug Metabolism and Pharmacokinetics·H OvermarsL C Post
Oct 1, 1995·Clinical Pharmacology and Therapeutics·O SpigsetR Dahlqvist
Sep 1, 1994·Clinical Pharmacokinetics·E PeruccaE Spina
Oct 1, 1993·Journal of Clinical Psychopharmacology·R Hoehn-SaricP A Hipsley
May 1, 1993·Pharmacopsychiatry·B OlivierM Tulp
Aug 1, 1996·Journal of Clinical Psychopharmacology·I M van VlietB R Slaap
Jan 1, 1995·Clinical Pharmacokinetics·J van Harten
Jan 1, 1996·European Journal of Clinical Pharmacology·U JeppesenK Brøsen
Feb 1, 1997·Journal of Clinical Psychopharmacology·G AbrahamR C Josiassen
Mar 21, 1998·The Journal of Clinical Psychiatry·H Y LaneW H Chang
Aug 26, 1998·Therapeutic Drug Monitoring·S HärtterC Hiemke
Nov 24, 1999·International Clinical Psychopharmacology·C L DeVaneR B Lydiard
Feb 7, 2001·Journal of Geriatric Psychiatry and Neurology·M E WylieC F Reynolds
Mar 15, 2001·The Journal of Clinical Psychiatry·C M PiontekK S Peindl
Jun 2, 2001·Journal of Clinical Psychopharmacology·A PalatnikJ Benjamin
Aug 3, 2001·The British Journal of Psychiatry : the Journal of Mental Science·V HendrickM V Brunhuber
Nov 13, 2002·Journal of Child and Adolescent Psychopharmacology·John WalkupUNKNOWN Research Units on Pediatric Psychopharmacology Anxiety Study Group
Jan 8, 2004·Journal of Clinical Psychopharmacology·Herman G M WestenbergLuigi M Barbato

❮ Previous
Next ❯

Citations

May 6, 2016·Expert Opinion on Pharmacotherapy·Massimiliano BuoliA Carlo Altamura
Jan 12, 2017·Expert Opinion on Drug Metabolism & Toxicology·Massimiliano BuoliMarta Serati
Jul 22, 2017·Expert Opinion on Pharmacotherapy·Massimiliano BuoliA Carlo Altamura
Sep 28, 2017·Current Treatment Options in Psychiatry·Elizabeth A CroccoKatherine Camfield

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Related Papers

CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
R P SwinsonC B Woszczyna
Primary Care Companion to the Journal of Clinical Psychiatry
Nikki Brannon, Dean Schuyler
Journal of the American Academy of Child and Adolescent Psychiatry
Boris BirmaherDavid A Brent
© 2022 Meta ULC. All rights reserved